Introducing HFX for PDN*

The only SCS system approved by the FDA with a specific indication for Painful Diabetic Neuropathy.

Meaningful Evidence

Nevro’s unique PDN indication is the outgrowth of years of investments in clinical trials culminating with the SENZA-PDN, the largest RCT evaluating SCS for PDN to date.


JAMA Neurology

Meaningful Evidence
10 KHz outcomes at 6 months

Excellent Safety and
Efficacy Profile

Within the SENZA-PDN, 10 kHz Therapy
demonstrated exceptional outcomes across
responder rates, pain relief, and even
sensory response.

Uniquely Possible
With 10 kHz Therapy

Historically, PDN patients have struggled with a
lack of treatment options when CMM fails.
Now, 10 kHz Therapy and a unique mechanism
of action offer new potential for relief.


Direct Neural Inhibition With
10 kHz Therapy

Uniquely Possible With 10 kHz Therapy

*HFX is a comprehensive solution that includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain. Throughout this presentation  HFXTM for PDN means that a patient has been implanted with a Senza System and programmed to include a frequency of 10 kHz.